Osmotica Pharmaceuticals is a holding company. Through its subsidiaries, Co. is focused on the development and commercialization of products that target markets with underserved patient populations. Co.'s promoted products include: M-72, which is for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 to 65; Arbaclofen ER, which is for the treatment of multiple sclerosis spasticity; and OS870, which is for the treatment of neurodegenerative disorder. Co.'s non-promoted products include Methylphenidate ER, which is for the treatment of ADHD and Venlafaxine ER tablets, which is for the treatment of depressive disorder and social anxiety disorder. The OSMT stock yearly return is shown above.
The yearly return on the OSMT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OSMT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|